Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM7ZJ4H)

• Drug Name: cicaprost Drug Info
• Synonyms: ZK 96480; ZK-96480

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5311044
  ChEBI ID: CHEBI:135578
  CAS Number: CAS 94079-80-8
  TTD Drug ID: DM7ZJ4H

Molecule-Related Drug Atlas

Drug(s) Targeting Prostaglandin E2 receptor EP1 (PTGER1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AS-013	DMD7XWS	Thrombosis	DB61-GB90	Phase 3	[6]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[7]
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[8]
ZD6416	DM46JIR	Pain	MG30-MG3Z	Discontinued in Phase 2	[9]
ONO-8130	DMBDCL4	Pollakiuria	MF50.1	Terminated	[10]
ONO-8711	DM2VRK7	Pain	MG30-MG3Z	Terminated	[11]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[7]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[3]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[12]
M&B 28767	DMJQG82	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Prostaglandin E2 receptor EP4 (PTGER4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[2]
RQ-00000007 (oral)	DMMYTRU	Pain	MG30-MG3Z	Phase 2	[13]
ONO-AE1-437	DMCUGI8	Asthma	CA23	Phase 2	[14]
BGC-20-1531	DMS2MQ5	Migraine	8A80	Phase 2	[15]
IK-007	DMBLFPN	Non-small-cell lung cancer	2C25	Phase 1/2	[16]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
E7046	DMFVT43	Rectal adenocarcinoma	2B92	Phase 1	[18]
ONO-4232	DMO4SD2	Acute heart failure	BD10-BD13	Phase 1	[19]
ONO-4578	DME63VK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
AN0025	DMGSYPY	Aggressive cancer	2A00-2F9Z	Phase 1	[20]

Drug(s) Targeting Prostaglandin E2 receptor EP2 (PTGER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[8]
Mycophenolate mofetil	DMPQAGE	Hepatosplenic T-cell lymphoma		Approved	[21]
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[22]
Iloprost	DMVPZBE	Pulmonary arterial hypertension	BB01.0	Approved	[23]
Omidenepag isopropyl	DMUX7Z8	Glaucoma/ocular hypertension	9C61	Approved	[24]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[25]
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[2]
CP-533536	DMZEJLB	Osteoporosis	FB83.0	Phase 2	[26]
Taprenepag	DM1TSHL	Glaucoma/ocular hypertension	9C61	Phase 2	[27]
TPST-1495	DM3GSB2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]

Drug(s) Targeting Prostaglandin E2 receptor EP3 (PTGER3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
16,16-dimethyl-PGE2	DMNF38S	Stem cell engraftment	QB63.8	Phase 2	[2]
ONO-9054	DM5O6GC	Glaucoma/ocular hypertension	9C61	Phase 2	[28]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[2]
BUTAPROST	DMVYNJZ	Discovery agent	N.A.	Patented	[8]
DG041	DMVO9WM	Peripheral vascular disease	BD4Z	Discontinued in Phase 2	[29]
GR-63799X	DM13GK8	Asthma	CA23	Discontinued in Phase 1	[30]
U46619	DM13FX4	Discovery agent	N.A.	Investigative	[3]
carbacyclin	DMMBQYE	Discovery agent	N.A.	Investigative	[2]
PGD2	DMYDW6J	Discovery agent	N.A.	Investigative	[7]
butaprost (free acid form)	DM5MZHP	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Prostacyclin receptor (PTGIR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Treprostinil	DMTIQF3	Pulmonary arterial hypertension	BB01.0	Approved	[31]
Selexipag	DMAHSU0	Pulmonary arterial hypertension	BB01.0	Approved	[32]
Epoprostenol	DMUTYR2	Allergic rhinitis	CA08.0	Approved	[33]
Dinoprost Tromethamine	DMXQKSL	Abortion	JA00	Approved	[34]
Misoprostol	DMHVJFK	Medical abortion	JA00.1Z	Approved	[34]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[25]
Beraprost	DML634R	Pulmonary hypertension	BB01	Phase 4	[35]
esuberaprost	DMXLGED	Gout	FA25	Phase 3	[36]
Ralinepag	DM7G4Y9	Pulmonary arterial hypertension	BB01.0	Phase 2	[37]
Clinprost	DM6E5VA	Asthma	CA23	Discontinued in Preregistration	[38]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[39]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[40]
Iloprost	DMVPZBE	Pulmonary arterial hypertension	BB01.0	Approved	[5]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[41]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[42]

Drug(s) Affected By Endothelin-1 (EDN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[43]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[44]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[45]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[46]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[47]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[48]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[49]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[50]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[51]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[52]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostacyclin receptor (PTGIR)	TTOFYT1	PI2R_HUMAN	Agonist	[2]
Prostaglandin E2 receptor EP1 (PTGER1)	TTG1QMU	PE2R1_HUMAN	Agonist	[3]
Prostaglandin E2 receptor EP2 (PTGER2)	TT1ZAVI	PE2R2_HUMAN	Agonist	[2]
Prostaglandin E2 receptor EP3 (PTGER3)	TTPNGDE	PE2R3_HUMAN	Agonist	[2]
Prostaglandin E2 receptor EP4 (PTGER4)	TT79WV3	PE2R4_HUMAN	Agonist	[3]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Endothelin-1 (EDN1)	OTZCACEG	EDN1_HUMAN	Gene/Protein Processing	[4]
Prostacyclin receptor (PTGIR)	OTWTABYM	PI2R_HUMAN	Protein Interaction/Cellular Processes	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1917).
• [2] Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24.
• [3] The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93.
• [4] Cyclooxygenase-2 acts as an endogenous brake on endothelin-1 release by human pulmonary artery smooth muscle cells: implications for pulmonary hypertension. Mol Pharmacol. 2002 Nov;62(5):1147-53. doi: 10.1124/mol.62.5.1147.
• [5] Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur J Biochem. 2002 Mar;269(6):1714-25. doi: 10.1046/j.1432-1327.2002.02817.x.
• [6] Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7.
• [7] Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41.
• [8] Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.Expert Opin Ther Pat. 2015 Jul;25(7):837-44.
• [9] The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology. 2003 Jan;124(1):18-25.
• [10] ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide-induced cystitis. Pain. 2011 Jun;152(6):1373-81.
• [11] Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development. Carcinogenesis. 2001 Dec;22(12):2001-4.
• [12] Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47.
• [13] Clinical pipeline report, company report or official report of Avarx.
• [14] An EP4 receptor agonist prevents indomethacin-induced closure of rat ductus arteriosus in vivo. Pediatr Res. 2004 Oct;56(4):586-90.
• [15] BGC20-1531, a novel, potent and selective prostanoid EP4 receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009 January; 156(2): 316-327.
• [16] Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation. Vet Med Sci. 2015 Dec 21;2(1):3-9.
• [17] Clinical pipeline report, company report or official report of Tempest Therapeutics.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] ONO-4232, an EP4-selective Agonist, Improves Left Ventricular Diastolic Dysfunction and Ameliorates Acute and Chronic Heart Failure in Animal Models. Circulation. 2012; 126: A15345.
• [20] AN0025, a novel antagonist of PGE2-receptor E-type 4 (EP4), in combination with total neoadjuvant treatment of advanced rectal cancer. Radiother Oncol. 2023 Aug;185:109669.
• [21] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
• [22] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [23] Exploration of prostanoid receptor subtype regulating estradiol and prostaglandin E2 induction of spinophilin in developing preoptic area neurons. Neuroscience. 2007 May 25;146(3):1117-27.
• [24] Clinical pipeline report, company report or official report of Santen Pharmaceutical.
• [25] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [26] Pfizer. Product Development Pipeline. March 31 2009.
• [27] A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17.
• [28] IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys. Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2547-52.
• [29] BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice. J Physiol Pharmacol. 2007 Sep;58(3):583-8.
• [30] Effects of the prostanoid EP3-receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat. Br J Pharmacol. 1999 Feb;126(4):849-58.
• [31] Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. 2009 Apr;157(4):625-35.
• [32] Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J. 2012 Oct;40(4):874-80.
• [33] Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol. 2009 May;46(5):682-94.
• [34] Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58.
• [35] Prostaglandin I2 IP Receptor Agonist, Beraprost, Prevents Transient Global Cerebral Ischemia Induced Hippocampal CA1 Injury in Aging Mice. J Neurol Disord. 2014;2:1000174.
• [36] Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9.
• [37] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [38] Protective effect of a prostaglandin I2 analog, TEI-7165, on ischemic neuronal damage in gerbils. Brain Res. 1997 Sep 26;769(2):321-8.
• [39] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [40] Mifepristone induced progesterone withdrawal reveals novel regulatory pathways in human endometrium. Mol Hum Reprod. 2007 Sep;13(9):641-54.
• [41] Genetic and ethnic risk factors associated with drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2010 Aug;10(4):280-90. doi: 10.1097/ACI.0b013e32833b1eb3.
• [42] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.
• [43] ?-adrenoceptors and muscarinic receptors mediate opposing effects on endothelin-1 expression in human lung fibroblasts. Eur J Pharmacol. 2012 Sep 15;691(1-3):218-24. doi: 10.1016/j.ejphar.2012.07.002. Epub 2012 Jul 13.
• [44] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [45] Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol. 2001 Nov-Dec;10(6):311-5. doi: 10.1016/s1054-8807(01)00095-3.
• [46] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [47] [Effect of simvastatin on endothelin-1 expression in endothelial cell cultured hypoxically]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Jan;39(1):72-5.
• [48] Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc Nutr Soc. 2008 Feb;67(1):42-7.
• [49] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [50] Nucleoside reverse transcriptase inhibitors induce a mitophagy-associated endothelial cytotoxicity that is reversed by coenzyme Q10 cotreatment. Toxicol Sci. 2013 Aug;134(2):323-34. doi: 10.1093/toxsci/kft105. Epub 2013 May 2.
• [51] Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007 Jun;85(5):408-14. doi: 10.1532/IJH97.E0620.
• [52] Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087. doi: 10.1155/2008/305087. Epub 2008 Dec 1.